Fig. 1 · Structure

Documents & Downloads

Hesperetin

Cat. No. A10449 CAS 520-33-2

PDE4 inhibitor

Hesperetin, a selective phosphodiesterase (PDE)4 inhibitor, is present in the traditional Chinese medicine, –Chen Pi.– Hesperetin is a citrus flavonoid that has been reported to lower plasma cholesterol. Hesperetin reduces the transcription of ACAT-2 mRNA in Hep-G2 cells and reduces ApoB protein synthesis in a dose-dependent manner. It also is a potential therapy for carcinoid cancer.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Hesperetin competitively inhibited tissue-derived guinea-pig PDE4 in a cAMP-hydrolysis assay, with a reported Ki of 45.6 ± 2.3 μM (mean ± SEM; n = 4). This result supports PDE4 inhibition under the assay conditions but does not establish PDE-family or PDE4-subtype selectivity. [1]

In a separate human recombinant PTP1B assay, hesperetin showed weak inhibition: IC50 288.01 ± 7.98 μM, compared with 9.65 ± 0.01 μM for ursolic acid. Values were reported as mean ± SEM of triplicate experiments. Potencies of hesperetin glycosides in that study should not be assigned to the aglycone. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Histamine receptor
TGF-β

Cellular Effect

Cell Line Activity Value Description Reference
BJ EC50 > 10 μM Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay [PMID: 20192247]
Caco-2 IC50 66.67 μM Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay [PMID: 28793973]
CCRF-CEM EC50 > 10 μM Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay [PMID: 20192247]
HCT-116 GI50 36.1 μM Anticlonogenic activity in human HCT116 cells after 6 days by crystal violet staining based assay [PMID: 27840137]
HeLa EC50 > 10 μM Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay [PMID: 20192247]
MCF7 EC50 > 10 μM Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay [PMID: 20192247]
Monocyte IC50 2.1 μM Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs [PMID: 8882428]
PC-3 IC50 40 μM Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay [PMID: 31398616]
PC-3 IC50 90 μM Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay [PMID: 31398616]
RAW264.7 CC50 > 100 μM Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay [PMID: 33667099]
RAW264.7 IC50 31.2 μM Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay [PMID: 33667099]
RAW264.7 IC50 48.59 μM Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess method [PMID: 33493826]
RPMI-8226 EC50 > 10 μM Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay [PMID: 20192247]
THP-1 EC50 > 10 μM Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method [PMID: 20192247]
U-266 EC50 > 10 μM Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay [PMID: 20192247]
Vero IC50 8.3 μM Inhibition of SARS coronavirus 3C-like protease cis-cleavage activity transfected in african green monkey Vero cells by luciferase reporter gene assay [PMID: 23647823]

16 records · Scroll to view more

Hesperetin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Hesperetin from 4 published references. In vitro models include human recombinant PTP1B assayed with p-nitrophenyl phosphate.

Hesperetin In Vitro Studies

In primary bovine aortic endothelial cells, hesperetin increased Akt, AMPK and eNOS phosphorylation and NO-sensitive fluorescence. The response to 10 μM hesperetin for 10 min was inhibited by L-NAME or wortmannin. These cellular findings do not establish direct kinase binding or human efficacy. [3]

Competitive inhibition of tissue-derived PDE4

Biochemical assay · PDE4 activity in guinea-pig lung or heart homogenate; Figure 1 does not distinguish the tissue source [1]

Hesperetin inhibited cAMP hydrolysis with kinetics interpreted by the authors as competitive. Rolipram served as a reference inhibitor. This experiment does not establish PDE-family or PDE4-subtype selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of PDE4-catalyzed cAMP hydrolysisKi 45.6 ± 2.3 μM; n = 4; mean ± SEM[1]
Reference inhibitor rolipram in the same assayKi 3.6 ± 1.8 μM; n = 5; mean ± SEM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10, 30 and 100 μM hesperetin
Exposure duration
30 min enzyme incubation at 37°C
Method
Radiometric cAMP-hydrolysis assay; Lineweaver–Burk analysis
Vehicle
Hesperetin stock dissolved in ethyl alcohol:DMSO (1:1); final assay solvent fraction not specified
Reported limits
Exact lung versus heart contribution and biological independence of n are not specified for Figure 1.
Methods and source locations

Compound reported in the paper: Hesperetin; Compound label in the paper: Hesperetin (paper material; stereochemistry unspecified)

Evidence concerns the reported hesperetin preparation at the aglycone identity level; no enantiomer-specific or supplier-lot performance claim.

Methods 2.1–2.2 and 2.6; Results 3.1; Figure 1a–b and caption

Inhibition of PDE4-catalyzed cAMP hydrolysis: Apparent Km versus inhibitor concentration, Figure 1a inset — Results 3.1; Figure 1a inset; Methods 2.6

Reference inhibitor rolipram in the same assay: Same kinetic analysis — Results 3.1; Figure 1b inset; Methods 2.6

Weak PTP1B inhibition by hesperetin aglycone

Biochemical assay · Human recombinant PTP1B assayed with p-nitrophenyl phosphate [2]

Hesperetin was a weak inhibitor under this assay, with a substantially higher reported IC50 than the positive control ursolic acid. More active glycosides in this paper are different materials.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PTP1B inhibition by hesperetinIC50 288.01 ± 7.98 μM; mean ± SEM of triplicate experiments (Table 1 footnote)[2]
PTP1B inhibition by positive-control ursolic acidIC50 9.65 ± 0.01 μM; mean ± SEM of triplicate experiments (Table 1 footnote)[2]

Literature-Reported Treatment Conditions

Exposure duration
10 min preincubation, followed by 20 min substrate reaction at 37°C
Method
pNPP hydrolysis; absorbance at 405 nm
Vehicle
Sample described as dissolved in 10% DMSO; final DMSO fraction not separately stated
Reported limits
Full IC50 dose series is not tabulated in the selected sections. IC50 is an assay endpoint, not a cell-treatment dose.
Methods and source locations

Compound reported in the paper: Hesperetin; Compound label in the paper: Hesperetin (paper material; stereochemistry unspecified)

Evidence concerns the reported hesperetin preparation at the aglycone identity level; no enantiomer-specific or supplier-lot performance claim.

Results 2.1; Table 1 hesperetin and ursolic acid rows and footnote a,d; Methods 4.1–4.2, 4.5

PTP1B inhibition by hesperetin: Log dose-inhibition curve; enzyme-free hydrolysis correction; ursolic acid positive control — Table 1 hesperetin row and footnote a; Methods 4.2

PTP1B inhibition by positive-control ursolic acid: Same assay — Table 1 ursolic acid row and footnotes a,d

Acute endothelial signaling and nitric oxide production

Cell-based study · Primary bovine aortic endothelial cells (BAEC), passages 3–5, serum-starved overnight [3]

Hesperetin increased Akt, AMPK and eNOS phosphorylation and the NO-sensitive fluorescent signal. L-NAME and wortmannin blocked the NO response; insulin and LPA provided pathway controls. This is a cellular response, not proof of direct kinase activation or human efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phospho-Akt Ser473, phospho-AMPK Thr172 and phospho-eNOS Ser1179Qualitative increase[3]
NO-sensitive fluorescence after hesperetin and inhibitor controlsQualitative response[3]

Literature-Reported Treatment Conditions

Treatment concentration
0, 0.01, 0.1, 1 and 10 μM for concentration series; 10 μM for time series and inhibitor-control experiment
Exposure duration
10 min for concentration series; 0, 1, 5, 10, 15 and 30 min for time series
Method
Immunoblotting and DAF-2-DA fluorescence in fixed BAEC
Co-treatment
For control experiments: L-NAME (100 μM) or wortmannin (100 nM), added 30 min before dye loading; insulin and LPA are comparator stimuli, not hesperetin combinations used to claim synergy.
Reported limits
Vehicle, hesperetin supplier/purity and enantiomer composition are not specified in the read main-text sections; Supplemental Data were not retrieved.
Methods and source locations

Compound reported in the paper: Hesperetin; Compound label in the paper: Hesperetin (paper material; stereochemistry unspecified)

Evidence concerns the reported hesperetin preparation at the aglycone identity level; no enantiomer-specific or supplier-lot performance claim.

Subjects and Methods: In vitro experiments; Results: Hesperetin acutely stimulates phosphorylation; Figure 1A–D and complete caption

Phospho-Akt Ser473, phospho-AMPK Thr172 and phospho-eNOS Ser1179: Immunoblots with β-actin loading control; five to six independent repeats, caption; densitometry mean ± SEM — Figure 1A–B and caption

NO-sensitive fluorescence after hesperetin and inhibitor controls: DAF-2-DA; concentration/time images repeated independently three times; inhibitor-control experiment five times, caption — Figure 1C–D and caption

Hesperetin In Vivo Studies

In aged male mice, dietary hesperetin at a reported 100 mg/kg/day beginning at 21 months increased median lifespan from 25.95 months with vehicle to 28.2 months (vehicle n = 8; hesperetin n = 19; log-rank p = 0.04). This model-specific result does not establish human lifespan extension or a PDE4-dependent mechanism. [4]

Late-life dietary hesperetin and mouse survival

Animal study · Naturally aged male wild-type mice on a pure or congenic C57BL/6 background [4]

Dietary hesperetin begun at 21 months was associated with longer survival than vehicle in this male-mouse experiment. Untreated versus vehicle survival was not significantly different. This does not demonstrate human longevity or establish that PDE4 inhibition caused the survival result.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival relative to vehicle dietMedian lifespan 28.2 months (hesperetin, n = 19) versus 25.95 months (vehicle, n = 8); log-rank p = 0.04[4]
Untreated versus vehicle survivalLog-rank comparison p = 0.5 (n.s.); untreated n = 20, vehicle n = 8[4]

Conditions shared by the study groups

Route
Oral, mixed into food
Frequency
Dietary administration; target daily dose reported
Treatment course
Initiated at 21 months; survival followed. Methods gives 3–6 months for other dietary experiments; that fixed course is not assigned to survival.
Vehicle
AIN-93G diet with 3.04% (w/w) propylene glycol
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dietary hesperetin versus vehicle in aged males
100 mg/kg/day as reported; diet contained 0.07% (w/w) hesperetin
Vehicle diet, n = 8; additional untreated control, n = 20; hesperetin, n = 19Median lifespan 28.2 months with hesperetin versus 25.95 months with vehicle; reported increase 2.25 months (8.7%); log-rank p = 0.04.[4]
Dietary hesperetin versus vehicle in aged males
Model: Male wild-type C57BL/6-background mice; treatment began at 21 months
Reported limits: Randomization and blinding for survival are not described in the selected methods; individual intake and enantiomer composition were not established.
Methods and source locations

Compound reported in the paper: Hesperetin; Compound label in the paper: Hesperetin (paper material; stereochemistry unspecified)

Evidence concerns the reported hesperetin preparation at the aglycone identity level; no enantiomer-specific or supplier-lot performance claim.

Methods: Mice and hesperetin treatment (Sec9), Statistical analysis (Sec22); Results Sec24–Sec25; Figure 1A and caption

Survival relative to vehicle diet: Survival curves; log-rank (Mantel–Cox) test — Results Sec25; Figure 1A and caption

Untreated versus vehicle survival: Log-rank test — Figure 1A caption

Dietary hesperetin versus vehicle in aged males · Methods: Mice and hesperetin treatment (Sec9), Statistical analysis (Sec22); Results Sec24–Sec25; Figure 1A and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 520-33-2
Applications PDE4 inhibitor
Formula C16H14O6
Molecular Weight 302.3
SMILES
COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 58 mg/mL (191.87 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Hesperetin Research References

  1. [1] Shih CH, Lin LH, Hsu HT, et al. Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia Evidence-based complementary and alternative medicine : eCAM (2012). PMID: 22454667 DOI: 10.1155/2012/472897 Source material
  2. [2] Ali MY, Jannat S, Jung HA, et al. Structural Bases for Hesperetin Derivatives: Inhibition of Protein Tyrosine Phosphatase 1B, Kinetics Mechanism and Molecular Docking Study Molecules (Basel, Switzerland) (2021). PMID: 34946519 DOI: 10.3390/molecules26247433 Source material
  3. [3] Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome The Journal of clinical endocrinology and metabolism (2011). PMID: 21346065 DOI: 10.1210/jc.2010-2879 Source material
  4. [4] Yeh CH, Shen ZQ, Wang TW, et al. Hesperetin promotes longevity and delays aging via activation of Cisd2 in naturally aged mice Journal of biomedical science (2022). PMID: 35871686 DOI: 10.1186/s12929-022-00838-7 Source material

Added to your cart

View Cart Checkout
Loading...